Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

BACKGROUND: Dapagliflozin is one of the novel glucose-lowering agents, which has recently been reported to reduce the risk of hospitalization for heart failure (hHF). The present study aimed to compare the differences between the risk of hHF after using dapagliflozin and dipeptidyl peptidase-4 inhib...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cardiovasc Diabetol
Main Authors: Seong, Jong-Mi, Kim, Jong Joo, Kim, Hae Jin, Sohn, Hyun Soon
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2020
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310428/
https://ncbi.nlm.nih.gov/pubmed/32571319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01060-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker